AMPGZ
Next report

Nov 16 2026in 39 days

EPS estimate

$0.12

Revenue estimate

$14M

EPS beats

3 of last 11

EPS surprise

2024: 50.0%2024: -360.0%2024: -33.3%2024: 29.4%2025: -158.3%2025: -12.5%2025: -50.0%2025: 88.9%2026: -100.0%2026: -20.0%2026: -500.0%
Apr 2 2024Aug 13 2026
ReportedEPS estEPS actualSurpriseRevenue estRevenue actualSurprise
Aug 13 2026($0.02)($0.12)-500.0%$8M$8M+0.9%
May 13 2026($0.05)($0.06)-20.0%$5M$5M+7.0%
Mar 26 2026($0.07)($0.14)-100.0%$4M-$4M-204.1%
Nov 14 2025($0.09)($0.01)+88.9%$5M$6M+21.9%
Aug 14 2025($0.06)($0.09)-50.0%$4M$11M+150.6%
May 15 2025($0.08)($0.09)-12.5%$3M$4M+20.0%
Mar 31 2025($0.12)($0.31)-158.3%$3M$2M-38.2%
Nov 14 2024($0.17)($0.12)+29.4%$3M$3M+3.7%
Aug 14 2024($0.12)($0.16)-33.3%$3M$3M-16.7%
May 28 2024($0.10)($0.46)-360.0%$4M$2M-43.9%
Apr 2 2024($0.08)($0.04)+50.0%$4M$4M+0.0%

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+64.84%
EPS—
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027E
Revenue Avg$36M$60M
Low$36M$60M
High$36M$60M
EBITDA Avg$-4M$4M
Low$-4M$4M
High$-4M$4M
EBIT Avg$-5M$2M
Low$-5M$2M
High$-5M$2M
Net Income Avg$-5M$2M
Low$-5M$2M
High$-5M$2M
EPS Avg$-0.26$0.08
Low$-0.26$0.08
High$-0.26$0.08
Analysts (Rev / EPS)1 / 11 / 1
Quarterly
MetricQ4 2026Q1 2027Q2 2027Q3 2027Q4 2027
Revenue Avg$9M$7M$20M$20M$13M
Low$9M$7M$20M$20M$13M
High$9M$7M$20M$20M$13M
EBITDA Avg$-2M$-2M$3M$4M$38,667
Low$-2M$-2M$3M$4M$38,667
High$-2M$-2M$3M$4M$38,667
EBIT Avg$-2M$-2M$3M$4M$-508,954
Low$-2M$-2M$3M$4M$-508,954
High$-2M$-2M$3M$4M$-508,954
Net Income Avg$-2M$-2M$2M$3M$-508,954
Low$-2M$-2M$2M$3M$-508,954
High$-2M$-2M$2M$3M$-508,954
EPS Avg$-0.08$-0.08$0.08$0.11$-0.02
Low$-0.08$-0.08$0.08$0.11$-0.02
High$-0.08$-0.08$0.08$0.11$-0.02
Analysts (Rev / EPS)1 / 11 / 11 / 11 / 11 / 1

Last reported Earnings history refreshes daily; a new report appears within about 2 daysAbout this data

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.